ENTITY
Kyowa Kirin Co Ltd

Kyowa Kirin Co Ltd (4151 JP)

93
Analysis
Health Care • Japan
Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.
more
•08 Sep 2020 13:02
Logo
468 Views
Share
•05 Sep 2020 06:00

Asia Short Interest Weekly: Tencent, SMIC, Meituan, Galaxy, Kao, Sumitomo, Alteogen, Genius, Largan

The Asia Short Interest weekly looks at moves in market wide short interest and highlights movements in stock specific short interest across Hong...

Logo
486 Views
Share
bullish•Fancl Corp
•06 Aug 2019 20:56

Fancl: Explanatory Meeting On Kirin's Stake Acquisition Light on Details but Stay Positive Anyway

At about 3:30pm JST news broke that Kirin Holdings (2503 JP) would acquire a 30.3% stake in Fancl Corp (4921 JP) from the company's founder and his...

Logo
Mio Kato
752 Views
Share
•12 May 2019 18:41

🇯🇵 Japan • Spring Results & Revisions & Market Update - Slip-Slidin' Away

SLIP-SLIDIN' AWAY - Japanese equities have lost 3.9% in the last holiday-shortened week and 4.6% or ¥30t since the bear-market rally peak on 17th...

Logo
692 Views
Share
•30 Oct 2018 23:21

Kyowa Hakko Kirin 3Q FY18 (YE Dec'18) Results - First Glance

Key highlights Continued genericization / ongoing price cuts led decline in domestic pharma sales by ~10% to ~¥43b However, overseas sales grew 16%...

x